William Jordan is co-chair of the Litigation & Trial Practice Group. He concentrates his practice on business litigation, government and internal corporate investigations, corporate ethics and compliance matters, and antitrust law. Bill is a member of the firm's Government Investigations & Special Matters Team and leads its Health Care Litigation Team. He frequently represents hospitals, pharmaceutical companies, insurers, health care providers, chemical manufacturers, telecommunications and technology providers, and financial services companies in offensive and defensive litigation, corporate compliance matters and government investigations. He also serves as outside ethics and compliance counsel to a number of companies, including multinational chemical and manufacturing companies and health care providers. Bill has represented companies in civil litigation throughout the country in complex matters involving unfair trade practices, antitrust law, health care regulation, civil RICO and the False Claims Act. He also has represented clients in government and congressional investigations involving health care fraud, the NSA’s terrorist surveillance program, computer crime and the Foreign Corrupt Practices Act.
From 2001-2003, Bill served as a senior official in the Department of Justice—from 2001-2003, as Senior Counsel to the Assistant Attorney General for the Civil Division; and in 2003, as Senior Counsel to the Associate Attorney General of the United States.
- Represented nation’s largest publicly-traded hospital chain in civil and criminal investigations throughout the country involving health care fraud matters. Negotiated favorable settlement of many investigations and obtained judicial dismissal of one matter involving allegedly unauthorized medical procedures.
- Represented New Orleans hospitals in criminal investigations and congressional hearings related to their response to Hurricane Katrina, including allegations that patients were euthanized in the immediate aftermath of the storm.
- Represented clients in state Attorneys General, Medicaid Fraud Control Unit, and federal investigations in over 20 states and in every federal circuit.
- Obtained $10.3MM judgment for a private college in civil RICO claim alleging fraud in theft of assets involving timber and real estate interests.
- Defended major telecommunications company in multiple class actions alleging that it had impermissibly revealed confidential customer information to government through the National Security Agency’s Terrorist Surveillance Program.
- Represented individual in Senate Judiciary Committee hearing related to alleged firing of U.S. Attorneys and political hiring at Department of Justice.
- Conducted numerous internal investigations related to alleged government fraud, FCPA issues and antitrust matters.
- Serve as outside global ethics and compliance counsel to world’s second largest chemical company.
-
Bill Jordan was quoted in a Global Trade magazine article discussing how giving business gifts to a foreign partner could possibly be viewed as a violation under the strict Foreign Corrupt Practices Act (FCPA) rules.
October 4, 2012
In the Press
-
One hundred and forty-seven Alston & Bird attorneys have been selected for inclusion in the 2013 edition of The Best Lawyers in America. The publication is universally regarded as among the few definitive guides to legal excellence, and its rankings are based on an exhaustive peer-review survey in which more than 36,000 leading attorneys cast almost 4.4 million votes on the legal abilities of other lawyers in their practice areas.
September 18, 2012
In the Press
-
Bill Jordan was quoted in an article for the FCPA Report’s two-part series titled “Designing a Facilitation Payments Policy to Minimize Liability and Retain Flexibility,” which discusses how most other jurisdictions prohibit facilitation payments to foreign officials and how some facilitation payments may violate local laws of foreign countries.
August 10, 2012
In the Press
-
September 7, 2010
In the Press
-
In recent years, the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) have aggressively investigated and enforced both the anti-bribery and accounting provisions of the Foreign Corrupt Practices Act (FCPA). Many of these matters have been the result of “industry sweeps,” which have included the oil and gas, pharmaceutical and medical device, and telecommunication industries.
DOJ and the SEC have also made clear that the banking and finance industry is a high priority for FCPA enforcement. This advisory discusses some of the pitfalls that hedge fund and private equity managers specifically may confront and provides guidance on how those risks can be minimized.
March 27, 2013
Advisories
-
In recent years, the pharmaceutical industry has been a frequent target of Foreign Corrupt Practices Act (FCPA) investigations. Since 2009, when Assistant Attorney General Lanny Breuer warned that the Department of Justice (DOJ) would be “intensely focused on rooting out foreign bribery in [the pharmaceutical] industry,” eight of the world’s 10-largest drugmakers have indicated that they may be facing FCPA liability, and many more have received letters of inquiry from DOJ. The government has paid particular attention to potentially improper payments associated with clinical trials conducted abroad. This article discusses recent developments in this arena and how pharmaceutical companies and medical device makers can best protect themselves from FCPA liability.
November 26, 2012
Publications
-
On November 14, 2012, the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) jointly released their long-anticipated guidance on the Foreign Corrupt Practices Act (FPCA). Entitled A Resource Guide to the U.S. Foreign Corrupt Practices Act (the “Resource Guide”), it does not contain ground-breaking legal revelations but does offer helpful information to companies transacting business in foreign countries. For example, it provides in-depth discussions on permissible gifts and payments under the FCPA, the definition of “foreign official,” FCPA risk in the merger and acquisition context, liability under the accounting provisions, and the keys to a successful compliance program. Although the Resource Guide is not legally binding, it contains practical guidance that can help companies operating abroad mitigate FCPA risk. This advisory discusses some of the Resource Guide’s more notable areas of guidance.
November 20, 2012
Advisories
-
The article discusses All-Payer Claims Databases (APCD) initiatives and, specifically, how these initiatives are not uniform, with various states taking different approaches to the purpose and implantation of APCDs. This presents thorny issues for those entities that are subject to the requirements of more than one APCD. In addition, the article discusses how implementation of the APCDs presents important issues concerning ERISA.
February 7, 2012
Advisories
-
16 January 2012
Publications
Past Events
-
January 24-25, 2013
Seminar
-
June 28, 2012
Seminar
-
May 22-23, 2012
Seminar
-
May 2, 2012
Seminar
-
March 20, 2012
Seminar
-
February 10-11, 2011
Seminar
-
January 27, 2011
Seminar
-
October 8, 2010
Seminar
-
September 2, 2010
Seminar
-
October 23, 2009
Seminar